TMCnet News
Cortendo AB: COR-003 Phase 3 Study Protocol to Be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & ExpoRegulatory News: Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing's syndrome at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo March 5-8 in San Diego, CA (News - Alert). This abstract will also be published in the April issue of Endocrine Reviews. Additional information on the Cortendo presentation: Title: An Open-label Study to Assess the Safety and Efficacy of Levoketoconazole (COR-003) in the Treatment of Endogenous Cushing's Syndrome (https://endo.confex.com/endo/2015endo/webprogram/Paper20580.html) Abstract: 20580
Location: Poster session, Expo Hall, San Diego Convention Center Posterboard: FRI-376 This abstract is available online: https://endo.confex.com/endo/2015endo/webprogram/Paper20580.html About Cortendo AB (http://www.cortendo.com) Cortendo AB is a global biopharmaceutical company incorporated in Sweden and based in the United States. The Company's initial strategic focus is to be the global leader in commercializing innovative medicines for orphan endocrine disorders. Cortendo is leading the way in the field of cortisol inhibition through the investigational drug, COR-003 (levoketoconazole) currently being studied in the global Phase 3 SONICS trial for the treatment of Cushing's syndrome. COR-003 (levoketoconazole) has received orphan designation from both the European Medicines Agency (EMA (News - Alert)) and the U.S. Food and Drug Administration (FDA). The Company's intent is to independently commercialize its Orphan/Endocrine assets in key global markets, and partner non-strategic product opportunities, such as diabetes, at relevant development stages. This information was brought to you by Cision http://news.cision.com |
